Fact CheckerSign in

NCT07292259CompletedPhase 2

Combination of Thalidomide and Hydroxyuria in Transfusion Dependent Thalasemmia

The Efficacy of Combined Thalidomide and Hydroxyurea Therapy in Transfusion Dependent β-thalassemia (TDBT), Phase II Trial

Source: ClinicalTrials.gov · Last updated 5 May 2026

Brief summary (registry, in English)

Beta thalassemia Major (BTM) is the most common hemoglobinopathy caused by mutations in the beta-globin gene . Worldwide, approximately 80 million people carry thalassemia gene mutation. Around 23,000 babies are affected by BTM each year, of which around 90% belong to low- or middle-income nations. In Pakistan, the carrier prevalence of thalassemia is 5-7% resulting in a significant population of approximately 10 million carriers in the general population. There are 50,000 thalassemia patients registered in treatment facilities around the country, one of the highest global prevalence rates for transfusion dependent BTM. The average life expectancy of BTM patients in Pakistan is around 10 years of age, while life expectancy in developed countries is around 50 to 60 years. This difference is due to poor transfusion support, transfusion-transmitted infections (TTIs) and inadequate iron chelation leading to hepatotoxicity and cardiac failure. The standard of care for BTM remains bone marrow transplantation or lifelong blood transfusions followed by iron chelation therapies. While standard care involves, challenges such as limited resources, lack of access to transplant services, and transfusion-related complications persist, particularly in low-and-middle-income countries.

Status (registry)
Completed
Phase (registry)
Phase 2
Study type
Interventional
Enrollment
100 (actual)
First submitted
13 Nov 2025
Start date
1 Jan 2024
Primary completion date
30 Dec 2025
Lead sponsor
Pakistan Blood and Marrow Transplant (PBMT) Group
Diseases
Thalassaemia
NCT number
NCT07292259

What you commit to

  • Study type: Interventional · Phase 2
  • Participants enrolled: 100
  • From 1 Jan 2024 to the primary completion date, 30 Dec 2025
  • 7 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Patients having cardiac, hepatic, pulmonary, renal or neurological dysfunction or history of thrombosis.

Age

  • Age less than two years.

Other

  • Both male and female participants of childbearing potential will be excluded due to the teratogenicity of thalidomide.

Who the study is looking for

  • Patients suffering from Transfusion Dependent β-thalassemia (TDBT) more than two years of age of either sex will be included in the study.

Age in the registry: 2 years to 12 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (7)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Armed Forces Bone Marrow Transplant Center
Coordinator of this site? Confirm its status
IslamabadPakistanUnknown status
AFBMTC (Clinical Trial and Research Cell)
Coordinator of this site? Confirm its status
RawalpindiPakistanUnknown status
AFBMTC (CT&RC), Medical Complex
Coordinator of this site? Confirm its status
RawalpindiPakistanUnknown status
AFBMTC, CMH Medical Complex
Coordinator of this site? Confirm its status
RawalpindiPakistanUnknown status
AFBMTC (CT&RC), CMH Medical Complex
Coordinator of this site? Confirm its status
RawalpindiPakistanUnknown status
Armed Forces Bone Marrow Transplant Center Rawalpindi Pakistan
Coordinator of this site? Confirm its status
RawalpindiPakistanUnknown status
Armed Forces Bone Marrow Transplant Center
Coordinator of this site? Confirm its status
RawalpindiPakistanUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.